You are here: Home » Current Affairs » Coronavirus » News
Business Standard

AstraZeneca vaccine set to become first to get approval in India: Report

The decision would pave the way for the vaccine's rollout in the world's second-most populous country

Topics
Coronavirus | Coronavirus Tests | Coronavirus Vaccine

Reuters 

Photo: Reuters
AstraZeneca Covid-19 vaccine. File Photo: Reuters

India’s drug regulator is set to approve on Friday a vaccine developed by and Oxford University for emergency use, three sources with knowledge of the matter said.

The decision would pave the way for the vaccine’s rollout in the world’s second-most populous country which, after the United States, has the highest number of COVID-19 infections in the world.

Britain and Argentina have already authorised the vaccine for urgent public use.

India’s Central Drugs Standard Control Organization (CDSCO), whose experts were meeting for the second time this week, could also approve a vaccine locally developed by Bharat Biotech, two of the sources said on condition of anonymity.

“Both and Bharat Biotech will get approval today,” said one of the sources. “All preparations are on with today’s date in mind.”

The other sources were less certain about Bharat Biotech’s prospects.

A CDSCO representative declined to comment. The group is meeting a day ahead of a nationwide trial run here for vaccine delivery in the country with more than 10 million infections.

More than 50 million doses of the vaccine have already been stockpiled by its local manufacturer, Serum Institute of India (SII), and one of the sources said the shots could start to be transported from cold storage to Indian states as early as Saturday.

SII did not immediately respond to an email request seeking comment.

The government said on Wednesday that Pfizer Inc had sought more time to present data for emergency authorisation of a vaccine it has developed with Germany’s BioNTech.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, January 01 2021. 16:02 IST
RECOMMENDED FOR YOU